Pre-made Brontictuzumab benchmark antibody ( Whole mAb, anti-NOTCH1 therapeutic antibody, Anti-AOS5/AOVD1/TAN1/hN1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-084

Pre-Made Brontictuzumab biosimilar, Whole mAb, Anti-NOTCH1 Antibody: Anti-AOS5/AOVD1/TAN1/hN1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Brontictuzumab (INN; development code OMP-52M51) is a humanized monoclonal antibody designed for the treatment of cancer.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-084-1mg 1mg 3090 Inquiry Inquiry

Size： 1mg | 10mg | 100mg

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Brontictuzumab biosimilar, Whole mAb, Anti-NOTCH1 Antibody: Anti-AOS5/AOVD1/TAN1/hN1 therapeutic antibody
INN Name Brontictuzumab
TargetNOTCH1
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesOncoMed Pharmaceuticals;University of Texas M. D. Anderson Cancer Center
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAdenoid cystic carcinoma;Solid tumours;Haematological malignancies;Colorectal cancer
Development Techna